10:21.62

UT06 Rec'd PCT 18 OCT 2002

PCTON

FORM 6-3

Practitio	ner's Docket No. <u>2605/1</u>	01 PATENT
ı	IN THE UNITED STATES P	ATENT AND TRADEMARK OFFICE
Patent app	plication	•
of		
for		Inventor(s)
	Tit	le of invention
		OR
In re applic	ation of: Miyata et al.	
Application Filed: For:	No.: 10/018,311 October 30, 2001 Meg-3 protein	Group Art Unit: N/A Examiner: N/A
	sioner for Patents ton, D.C. 20231	
B) NOTE: "A thi	STATEMENT WITHIN TEFORE MAILING OF FIRST In information disclosure statement shall be tree months of the filing date of a national	ENTAL INFORMATION DISCLOSURE THREE MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) The considered by the Office if filed by the applicant. (1) within application; (1) within three months of the date of entry of the international application; or (3) before the mailing date of a first to occurs last." 37 CF.R. § 1.97(b)
	(When using Express Mail, the	ER 37 C.F.R. § 1.8(a) and 1.10* Express Mail label number is mandatory; certification is optional.)
I hereby cer	tify that this correspondence is, on the	date shown below, being:
		MAILING
	sited with the United States Postal Servints, Washington, D.C. 20231	rice in an envelope addressed to the Commissioner for
	C.F.R. § 1.8(a)	37 C.F.R. § 1.10*
□ with	sufficient postage as first class mail.	■ as "Express Mail Post Office to Addressee" Mailing Label No EL289073660US
		ANSMISSION
□ transmiπe	ed by facsimile to the Patent and Trade	mark Office.
Date: Oct	ober 18, 2002	1////
		Signature

Morton Chirnomas (type or print name of person certifying)

OCT 1 8 2002 3 NO.

NOTE: The "filing date of a national application" under 37 C.F.R. § 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark Office, the filing is defined in 37 C.F.R. § 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. § 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the basic national fee; (2) a copy of the international application, unless already sent by the International Bureau, and optionally an English translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. The optional items must be submitted later, with surcharges. 37 C.F.R. § 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

- NOTE: "No certification or fee is due when the filing Is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."
- NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 CF.R. 1.10. An Office action is mailed on the date Indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).
- NOTE: "The term national application' Includes continuing applications (continuations, divisions, continuationsin-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).
- NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 CF.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosures statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).
- **WARNING:** "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. § 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner.' Notice of July 6, 1992 (1141 O.G. 63).

Reg. No.: 34465

Signature of Practitioner

Tel. No.: 617/443-9292

Morton Chirnomas.

(type or print name of practitioner)

Customer No.: 00-2101

Bromberg & Sunstein LLP 125 Summer Street, Boston, MA 02110

Practitioner's Docket No	2605/101	PATENT
IN THE UNITED STATES	S PATENT AND TR	ADEMARK OFFICE
Patent application		
of		
	Inventor(s)	
for		
	Title of invention	
	OR	
In re application of: Miyata et al.		
Application No.: 10/018,311 Filed: October 30, 2001 For: Meg-3 protein	Group Art Unit: Examiner:	N/A N/A
(When using Express Mail	RMATION DISCLOS JNDER 37 C.F.R. § 1.8(a) a I, the Express Mail label num Mail certification is optional	and 1.10* nber is mandatory;
I hereby certify that this correspondence is, on	the date shown below, beir	ng:
	MAILING	
deposited with the United States Postal Patents, Washington, D.C. 20231 37 C.F.R. § 1.8(a)	Service in an envelope add	
☐ with sufficient postage as first class ma		s Mail Post Office to Addressee" bel No. EL289073
	TRANSMISSION	
\square transmitted by facsimile to the Patent and T	rademark Office.	
Date: October 18, 2002	Signature	
	_Morton_Chirnoma	s
	(type or print name o	

(Information Disclosure Statement [6-1]--page 1 of 6)



NOTE: "An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods:

- (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- (3) Before the mailing date of a first Office action on the merits; or
- (4) Before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114."

37 C.F.R. § 1.97(b).

NOTE: "Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section." 37 C.FR. § 1.56(a).

"Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application." 37 C.F.R. § 1.56(c).

NOTE: The "duty as described in § 1.56 will be met so long as the information in question was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98 before issuance of the patent." Notice of January 9, 1992, 1135 O. G. 13 -25 at 17.

WARNING: "No information disclosure statement maybe filed in a provisional application." 37 C.FR. § 1.51(d).

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement: (check sections forming a part of this statement: discard unused sections and number pages consecutively)

 Preliminary Statement 	is
---	----

- 2. FORMS PTO/SB/08A and 08B (formerly FORM PTO-1449)
- 3.

 Statement as to Information Not Found in Patents or Publications
- 4. ☐ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted
- 5.

 Cumulative Patents or Publications
- 6. Copies of Listed Information Items Accompanying This Statement
- 7. Concise Explanation of Non-English Language Listed Information Items
 - ☑ 7A. EPO Search Report
 - 7B. English Language Version of EPO Search Report
- 8. Translation(s) of Non-English Language Documents
- 9. Concise Explanation of English Language Listed Information Items (Optional)
- 10. Identification of Person(s) Making This Information Disclosure Statement

(complete the following, if appropriate)

Sections

, respectively, have been continued on ADDED PAGE(S).

NOTE: "Once the minimum requirements are met the examiner has an obligation to consider the information." Notice of April 20, 1992 (1138 O.G. 37-41, 37).

(Information Disclosure Statement [6-1]--page 2 of 6)



Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

EU 1 8 2962

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Miyata et al.

Attorney Docket:

2605/101

Serial No:

10/018,311

Art Group Unit:

Not yet assigned

Date Filed:

October 30, 2001

Examiner Name:

Not yet assigned

Invention:

MEG-3 PROTEIN

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

Other Documents

Examiner

Ref.

Title of Article, Title of Item, Date, Pages

Initials

No.

AH DATABASE EMBL 'Online!

15 June 1998 (1998-06-15)

ZHANG WP ET AL.: "BE0002 monocyte-derived dendritic cell library Homo sapiens cDNA HDA003 5', mSRNA sequence" retrieved from EMBL Database Accession No. AI003761

XP002200765 *abstract*

Examiner Signature:
Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Section 6. Copies of Listed Information Items Accompanying This Statement

NOTE: 37 C.F.R. § 198(a)(2) requires that any information disclosure statement filed under § 1.97 shall include:

"A legible copy of.:

- (i) Each U.S. patent application publication and U.S. and foreign patent;
- (ii) Each publication or that portion which caused it to be listed,
- (iii) For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion. . .

Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

(complete the following, if applicable)

Exception(s) to above:

Items in prior application, from which an earlier filing date is claimed for this application, as identified in Section 4.
Cumulative patents or publications identified in Section 5.



Section 10. Identification of Person(s) Making This Information Disclosure Statement

The person making thi	s statement is	
	(check each appl	icable item)
(a) □ the inver	ntor(s) who signs below	
	SIG	NATURE OF INVENTOR
	(typ	pe or print name of inventor who is signing)
	dual associated with the plication (37 C.F.R. § 1.	
	SIG	NATURE OF INVENTOR
	(typ	pe or print name of inventor who is signing)
(c) ■ the practi	tioner who signs below	on the basis of the information:
	<i>(check each</i> appli	cable item)
	supplied by the invento	or(s).
	supplied by an individu of this application. (37 (al associated with the filing and prosecution C.F.R. § 1.56(c))
•	in the practitioner's file.	B1111
Reg. No.: 34465		Ille.
-	SIG	NATURE OF PRACTITIONER
Tel. No.: 617/443-9292		Morton Chirnomas be or print name of practitioner)
Customer No.: 00-2101		omberg & Sunstein LLP 5 Summer Street, Boston, MA 02110

(Information Disclosure Statement-Section 10. Identification of Person(s) Making This Information Disclosure Statement [6-1]-page 6 of 6)

02605/00101 222863.1

MC/nsj

PLEASE DATE STAMP AND RETURN The Commissioner for Patents has received from Bromberg & Sunstein LLP the following re:

Express Mail No. EL289073660US () Issue Fee Transmittal & Form PTOL-85b () Petition for _____ month Extension ___ Maintenance Fec () Transmittal of Formal Drawings Docket No: 2605/101 (M DS & References AH Date: 10/18/02 () Amendment (Preliminary) () Check in the amount of \$__ () Amendment Transmittal Examiner: N/A Art Unit: N/A () Response () Payment of Filing/Issue Date: October 30, 2001 () Assignment/Recordation Form Cover Sheet Miyata et al. Scriat/Patent No: 10/018,311 () Provisional Application Cover Sheet () Completion of Filing Requirements Meg-3 protein () Declaration & Power of Attorney () executed () unexecuted Documents:
() New Application Transmittal () Description - ______pages sheets of drawings () formal () informal () Claims - pages () Small Entity Statement () Abstract Inventor Tige Tige

() Request for Corrected Filing Receipt